| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $3.2M | 0.00% | 1.98M | −14% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AUTL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for AUTL.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -31.2 | 24.8 | -19.3 | 2.2 | 32.6 | -14.4 | -6.9 | 57.7 | -17.4 | -16.5 | −18.6% | ||
| 2025 | -6.0 | -21.7 | -10.4 | -9.0 | 24.1 | 30.3 | 5.3 | -37.5 | 8.7 | -4.9 | -9.0 | 41.1 | −15.3% |
| 2024 | -6.5 | -0.3 | 6.3 | -42.3 | 13.9 | -16.9 | 34.8 | -16.2 | -7.6 | -7.2 | -1.5 | -29.2 | −63.5% |
| 2023 | 13.2 | -9.8 | -5.2 | -1.6 | 71.8 | -23.5 | 35.7 | -0.6 | -27.4 | 21.0 | 51.8 | 50.5 | +238.9% |
| 2022 | -23.1 | -6.3 | 11.5 | -25.2 | -12.2 | 3.3 | -1.4 | 18.3 | -35.2 | 33.2 | -7.4 | -28.0 | −63.4% |
| 2021 | -17.8 | -12.4 | -11.0 | 1.6 | 13.9 | 0.2 | -19.9 | 29.1 | -4.7 | -14.8 | 15.2 | -19.3 | −41.9% |
| 2020 | -25.6 | -16.7 | -26.8 | 57.3 | 32.9 | 28.0 | -17.7 | 11.1 | -20.7 | -7.1 | -3.0 | -14.8 | −32.3% |
| 2019 | -19.6 | 3.6 | 15.1 | -16.8 | -21.2 | -22.0 | -4.2 | -32.9 | 20.0 | -3.6 | 25.3 | -12.0 | −59.8% |
| 2018 | -12.4 | 26.5 | 3.3 | -7.1 | 36.9 | -15.8 | +22.6% |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Buy / hold / sell counts